Australia
· Delayed Price · Currency is AUD LTR Pharma Statistics
Total Valuation
LTR Pharma has a market cap or net worth of AUD 70.58 million. The enterprise value is 36.51 million.
| Market Cap | 70.58M |
| Enterprise Value | 36.51M |
Important Dates
The next estimated earnings date is Tuesday, May 27, 2025.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LTR Pharma has 180.98 million shares outstanding. The number of shares has decreased by -47.24% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 180.98M |
| Shares Change (YoY) | -47.24% |
| Shares Change (QoQ) | +9.97% |
| Owned by Insiders (%) | 8.23% |
| Owned by Institutions (%) | 0.86% |
| Float | 97.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 141.25 |
| PB Ratio | 2.06 |
| P/TBV Ratio | 2.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.35 |
| EV / Sales | 73.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.90 |
Financial Position
The company has a current ratio of 79.99
| Current Ratio | 79.99 |
| Quick Ratio | 79.99 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18,939.21 |
Financial Efficiency
Return on equity (ROE) is -33.62% and return on invested capital (ROIC) is -20.94%.
| Return on Equity (ROE) | -33.62% |
| Return on Assets (ROA) | -20.56% |
| Return on Invested Capital (ROIC) | -20.94% |
| Return on Capital Employed (ROCE) | -19.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +58.00% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 46.00 |
| Average Volume (20 Days) | 87,933 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LTR Pharma had revenue of AUD 499,707 and -6.82 million in losses. Loss per share was -0.05.
| Revenue | 499,707 |
| Gross Profit | 931,202 |
| Operating Income | -6.80M |
| Pretax Income | -6.82M |
| Net Income | -6.82M |
| EBITDA | n/a |
| EBIT | -6.80M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 34.07 million in cash and n/a in debt, giving a net cash position of 34.07 million or 0.19 per share.
| Cash & Cash Equivalents | 34.07M |
| Total Debt | n/a |
| Net Cash | 34.07M |
| Net Cash Per Share | 0.19 |
| Equity (Book Value) | 34.30M |
| Book Value Per Share | 0.19 |
| Working Capital | 34.23M |
Cash Flow
In the last 12 months, operating cash flow was -5.28 million and capital expenditures -10,639, giving a free cash flow of -5.29 million.
| Operating Cash Flow | -5.28M |
| Capital Expenditures | -10,639 |
| Free Cash Flow | -5.29M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 186.35% |
| Operating Margin | -1,360.63% |
| Pretax Margin | -1,365.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LTR Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 47.24% |
| Shareholder Yield | 47.24% |
| Earnings Yield | -9.67% |
| FCF Yield | -7.50% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LTR Pharma has an Altman Z-Score of 176.42.
| Altman Z-Score | 176.42 |
| Piotroski F-Score | n/a |